Introduction

40
Cancer is a leading cause of morbidity and mortality in industrialised nations, with 41 failed treatment being often life-threatening. While a wide range of drugs are now 42 available to treat cancer patients, in practice only a small proportion of them respond 43 to these drugs [1] . To make things worse, our current ability to identify responsive 44 patients before treatment is still very limited [2] . This situation has a negative impact 45 on patient survival (the tumour keeps growing until an effective drug is administered), 46 healthcare costs (very expensive drugs are ineffective, and thus wasted, on most 47 cancer patients [1, 3] ) and the success rates of oncology clinical trials (10% fall in 48
Phase II studies, with the number of phase III terminations doubling in recent years 49 [4] ). Therefore, there is a pressing need to understand and predict this aspect of 50 human variation to make therapy safer and more effective by determining which 51 drugs will be more appropriate for any given patient. 52
The analysis of tumour and germline DNA has been investigated as a way to 53 personalise cancer therapies for quite some time [5] . However, the recent and 54 comprehensive flood of new data from much cheaper and faster Next Generation 55 Sequencing (NGS) technologies along with the maturity of more established 56 molecular profiling technologies represents an unprecedented opportunity to study the 57 molecular basis of drug response. These data have shown that drug targets often 58 present genomic alterations across patient tumours [6] . At the molecular level, these 59 somatic mutations affect the abundance and function of gene products driving tumour 60 growth and hence may influence disease outcome and/or response to therapy [7] . 61 Therefore, there is opportunity for genetic information to aid the selection of effective 62 therapy by relating the molecular profile of tumours to their observed sensitivity to 63 drugs. Research on the identification of drug-gene associations that can be used as 64 predictive biomarkers of in vitro drug response is carried out on human cancer 65 tumour-derived cell lines [8] [9] [10] . Cell lines allow relatively quick and cheap 66 experiments that are generally not feasible on more accurate disease models [11] . 67
Here the molecular profile of the untreated cell line is determined and a phenotypic 68 readout is made to assess the intrinsic cell sensitivity or resistance to the tested drug. 69
In addition to biomarker discovery [8] [9] [10] , these data sets have also been used to 70 enable pharmacogenomic modelling [12] [13] [14] , pharmacotranscriptomic modelling [15, 71 16 ], QSAR modelling [17, 18] , drug repositioning [18, 19] and molecular target 72 identification [19] [20] [21] , among other applications. 73
Our study focuses on the Genomics of Drug Sensitivity in Cancer (GDSC) data 74 analysed by Garnett et al. [9] and publicly released after additional curation [22] . The 75 released data set comprises 638 human tumour cell lines, representing a broad 76 spectrum of common and rare cancer types. One benefit of looking at a large number 77 of cell lines is that the pool of data becomes larger, which is beneficial for in vitro 78 biomarker discovery. These authors profiled each cell line for various genetic 79 abnormalities, including point mutations, gene amplifications, gene deletions, 80 microsatellite instability, frequently occurring DNA rearrangements and changes in 81 gene expression. Thereafter, the sensitivity of 130 drugs against these cell lines was 82 measured with a cell viability assay in vitro (cell sensitivity to a drug was summarised 83 by the half-maximal inhibitory concentration or IC 50 of the drug-cell pair). A p-value 84 was calculated for 8637 drug-gene associations using a MANOVA test (P MANOVA ), 85 with 396 of those associations being above a FDR=20% Benjamini-Hochberg [23] 86 adjusted threshold and thus deemed significant (full details in the Methods section). 87
Overall, it was found that only few drugs had strong genomic markers, with no 88 actionable mutations being identified for 14 drugs. 89
However, a statistically significant drug-gene association is not necessarily a useful 90 genomic marker of in vitro drug response. Indeed, significant p-values are merely 91 intended to highlight potential discoveries among thousands of possibilities and thus 92 their practical importance still have to be evaluated for the problem at hand [24] [25] [26] . 93
In this context, this means assessing how well the gene mutation discriminates 94 between cell lines from an independent test set according their sensitivity to a given 95 drug. Importantly, while a parametric test such as MANOVA makes strong modelling 96 assumptions [27] (e.g. normality and equal variances in the distribution of residuals), 97 the distribution of drug responses of the compared groups of cell lines is often 98 skewed, contain outliers and/or have different variances. Consequently, p-values from 99 the MANOVA test may lead to two types of errors at the inter-association level, a 100 false association (type I error or false positive) or a missed association (type II error or 101 false negative). False negatives are the most worrying types of errors because these 102 are hard to detect and can have particularly adverse consequences (e.g. missing a 103 genomic marker able to identify tumours sensitive to a drug for which no marker have 104
been found yet). Thus, research intended to identify more appropriate statistical 105 procedures for biomarker discovery on comprehensive pharmacogenomic resources 106 such as GDSC is crucial to make the most out of these valuable data. 107
Here we will investigate the impact of MANOVA modelling assumptions on the 108 systematic identification of genomic markers of drug sensitivity on GDSC 109 pharmacogenomic data. The assessment will be carried out by comparing drug-gene 110 associations from the MANOVA test with those identified by Pearson"s χ 2 test, which 111 as a non-parametric test [28] does not make strong modelling assumptions distorting 112 the detection task. This χ 2 test is applied to binary classification and hence we propose 113 here an auxiliary threshold to enable its application to this problem. Furthermore, the 114 largest discrepancies between both tests on the training data set will be visualised and 115 discussed with respect to the discriminative power of its significant and non-116 significant drug-gene associations. Importantly, we introduce a benchmark using a 117 more recent GDSC dataset than that employed for the identification of statistically 118 significant drug-gene associations and use it to validate in vitro the single-gene 119 markers arising from each statistical test. This is timely research because the issue of 120 systematically validating markers in vitro has not been addressed yet and thus it is 121 currently unknown to which extent the limitations of the statistical test affect genomic 122 marker discovery. 123
Results
124
Improved measurement of discriminative power by the χ 2 test 125 Genomic markers of drug response aim at identifying gene alterations that best 126 discriminate between tumours regarding their sensitivity to a given drug. The 127 ANOVA family of statistical tests attempts to determine how discriminative is the 128 gene alteration by comparing the intra-group variances with the inter-group variance, 129 with the sample variance being considered the optimal procedure to estimate these 130 variances [29] . In order to measure the discrimination of a marker directly, we 131 introduce instead an optimal IC 50 threshold to define two auxiliary classes of cell 132 lines, those most sensitive to the drug and those most resistant to the drug, which 133 permits posing biomarker evaluation as a binary classification problem. Thus, we 134 characterise each group of cells, i.e. those with the mutated gene and those with the 135 wild-type (WT) gene, by its median IC 50 and define this mutation-dependent threshold 136 as the mean of both medians (e.g. the dotted red line of the scatter plot in Figure 2A ). 137 This is an optimal definition in that the size of each group and their outliers do not 138 alter the position of this decision boundary, which is equidistant to both classes and 139 leads to an intuitive notion of class membership as distance from the threshold. 140
Once this IC 50 threshold is calculated, the mutation-based prediction of drug response 141 of a cell line can be categorised as a true positive (TP), true negative (TN), false 142 positive (FP) or false negative (FN). These relative measures of drug sensitivity are 143 only intended to quantify the discrimination between mutated and WT cell lines and 144 must not be mistaken by absolute measures of drug sensitivity (e.g. a cell line can be 145 defined as sensitive to a drug if its IC 50 is better than the median IC 50 of all cell lines 146 for that drug, however such threshold may poorly measure how different are the drug 147 responses of mutated and WT tumours). From this contingency table at the intra-148 association level, the discrimination offered by a drug-gene association can be 149 summarised by its Matthews Correlation Coefficient (MCC) [30] . Because the 150 definition of a positive instance depends on whether the somatic mutation is 151 sensitising or resistant (see the Methods section), MCC can only take values from 0 152 (gene mutation have absolutely no discriminative power) to 1 (gene mutation 153 perfectly predicts whether cell lines are sensitive or resistant to the drug). 154
Furthermore, since cells are now partitioned into four non-overlapping categories with 155 respect to their response to a drug, the χ 2 test can be computed from this 2x2 156 contingency table to identify those drug-gene associations with statistically significant 157 discriminative power (the χ 2 statistic measures how far is the contingency table 158 obtained by the classification method from the values that would be expected by 159 chance). The process is sketched in Figure 2 and leads to an alternative set of p-values 160 from the χ 2 test (P χ2 ). To establish which associations are significant according to the 161 χ 2 test, we also calculated for this case the FDR=20% Benjamini-Hochberg adjusted 162 threshold (0.00940155). Overall, 403 statistically significant drug-gene associations 163 were found using the χ 2 test from the same set of 8637 associations that were 164 downloaded (i.e. seven significant associations more than with the MANOVA test). 165 Importantly, only 171 associations of these markers were found by the MANOVA 166 test. These deviations of the MANOVA test with respect to the results provided by the 167 non-parametric test will be investigated in the next section to highlight potential false 168 and missed biomarkers. 169 A last aspect to discuss about the proposed methodology is the duality of MCC and χ 2 . 170
In statistics, MCC is known as the φ coefficient, which was introduced [31] by Yule in 171 1912 and later rediscovered [30] by Matthews in 1975 as the MCC (interestingly, 172 despite being more recent, the MCC has become a much more popular metric for 173 binary classification than the φ coefficient [32-37]). As χ 2 = n•φ 2 holds[31], so does 174 χ 2 =n•MCC 2 with n being the number of tested cell lines for the considered drug and 175 thus MCC will be highly correlated with P χ2 . To avoid confusion, we will use φ to 176 refer to discrimination at this intra-association level (i.e. to identify the markers) and 177 reserve MCC for the validation of the identified markers as a separate binary 178 classification problem at the inter-association level that we will introduce later. Figure  179 3A presents the number of drug-gene associations for each number of tested cell lines, 180 from which it is observed that each drug has only been tested on a subset n of the 638 181 cell lines (i.e. gene associations for a given drug will be all evaluated on the same 182 number of cell lines n). Two distinctive groups of drugs emerge: those tested on 183 around 300 cell lines (red bars) and those tested around 450 cell lines (black bars). 184 Figure 3B shows that φ and -logP χ2 are highly correlated even across different n (for 185 associations with the same n, a perfect Pearson and Spearman correlation is obtained 186 as expecteddata not shown). Given the observed φ distribution of n values, all 187 markers with an φ of 0.15 or more are found unlikely to have arisen by chance. This 188 connexion is useful in that φ is widely used [32-37] but without establishing its 189 statistical significance for the tackled problem instance. 190 Potential false-positive and false-negative markers of the MANOVA test 191 We have introduced a new method directly measuring the discriminative power of a 192 drug-gene association using the φ along with its significance using P χ2 . We analyse 193 next those associations where the MANOVA test deviates the most from this non-194 parametric test. First, we identified the association with the largest difference between 195 P MANOVA and P χ2 among those not significant by the χ 2 test. The left scatter plot in 196 Figure 4 shows that this drug-gene association (GW441756-FLT3) discriminates 197 poorly between mutant and WT cell lines despite a very low P MANOVA~1 0 -10 . In 198 contrast, a high P χ2~1 0 -1 is obtained which means that the χ 2 test rejected this potential 199 false positive of the MANOVA test. 200
Conversely, to assess the consistency of the MANOVA test, we searched for the drug-201 gene association with smallest P χ2 among those with a similar P MANOVA to that of 202 GW441756-FLT3, which is Dasatinib-BCR_ABL (Figure 4 right). The BCR_ABL 203 translocation is a highly discriminative marker of Dasatinib sensitivity (φ =0.65), as 204 evidenced by the barely overlapping drug response distributions from each set of cell 205 lines. Note that, whereas the p-value for Dasatinib-BCR_ABL is of the same 206 magnitude as that for GW441756-FLT3 using the MANOVA test (P MANOVA~1 0 -10 ), 207 the p-values for the same associations using the χ 2 test are almost 27 orders of 208 magnitude apart. Thus, unlike the χ 2 test, the MANOVA test is unable to detect the 209 extreme difference in discriminative power offered by these two drug-gene 210
associations. 211
The next experiment consists in searching for the largest discrepancy in the opposite 212 direction. First, we identified the association with the largest difference between 213 P MANOVA and P χ2 , this time among those not significant by the MANOVA test. The 214 left scatter plot in Figure 5 shows marked difference in the two drug response 215 distributions of this drug-gene association (Dasatinib-CDKN2a.p14), suggesting that 216 this is a potential false negative of the MANOVA test despite a high P MANOVA~1 0 -1 . In 217 contrast, a low P χ2~1 0 -9 is obtained, which means that the χ 2 test detected this 218 potential false negative of the MANOVA test. Conversely, to assess again the 219 consistency of the MANOVA test, we searched for the drug-gene association with 220 smallest P MANOVA among those with a similar P χ2 to that of 221 which is SB590885-BRAF ( Figure 5 right) . Whereas the p-values for CDKN2a.p14 and SB590885-BRAF differ 27 orders of magnitude using the 223 MANOVA test, the p-values for the same associations have similar p-values using the 224 χ 2 test (P χ2~1 0 -9 ). Thus, unlike the χ 2 test, the MANOVA test is unable to detect that 225 both markers have similar discriminative power as also indicated by the MCC 226 (SB590885-BRAF has a φ of 0.29 for 0.35 of Dasatinib-CDKN2a.p14). 227
Validation of single-gene markers on a more recent GDSC data set 228 We propose a new benchmark based on using the most recent comparable GDSC data 229 as test sets. For the 127 drugs in common between releases 1 and 5, two non-230 overlapping data sets are generated per drug. Training sets from data in release 1 231 along with their logIC 50 s for the considered drug, which were used to identify 232 genomic markers as previously explained. Further, test sets contain the new cell lines 233 tested with the drug in release 5. Thereafter, the significant drug-gene associations 234 from each statistical test are evaluated on these test sets. Previously, a cell line 235 sensitivity threshold was defined to discriminate between those resistant or sensitive 236 to the considered drug. For each drug, we calculated the threshold as the median of all 237 the logIC 50 values from training set cell lines. Consequently, cell lines with logIC 50 238 lower than such threshold are sensitive to the drug of interest, whereas those with 239 logIC 50 higher the threshold are resistant. Lastly, classification performance of a 240 marker on its test set is summarised with the MCC. 241 Figure 6 presents a comparison between detection methods using this benchmark. The 242 three compared methods are those based on the χ 2 test (B), the MANOVA test (C) and 243 their consensus (A; the association is significant if it is significant by both tests). We 244 can see that the consensus method is the most predictive (full results in additional file 245 1), followed by associations only significant with the χ 2 test (additional file 2) and 246 those only significant by the MANOVA test (additional file 3). These results show 247 that the overall predictive value of the markers revealed by the χ 2 test is higher than 248 that arising from the MANOVA test and also that the consensus of both tests is more 249 predictive than any of these two tests alone. While most of the markers provide better 250 prediction than random classification ( New genomic markers are particularly valuable in those drugs for which no marker is 287 known yet. From our analysis, we have also identified seven new markers with MCC 288 better than random classification for the five drugs for which the MANOVA test did 289 not find any potential marker [9]: NU-7441, Cyclopamine, BI-2536, Gemcitabine and 290 Epothilone B (see Additional file 2). Figure 8 shows the performance of two of these 291 markers. On the right, the mutational status of the NOTCH1 gene is the most 292 discriminative marker for the development drug BI-2536 (MCC=0.23 on the test set). 293
On the left, EWS_FLI1-positive cell lines exhibit increased sensitivity to 294 Gemcitabine (MCC=0.18 on the test set). 295
Discussion
296
To improve the search of genomic markers of drug response, we have presented a new 297 non-parametric approach that directly measures the discriminative power of a drug-298 gene association by posing it as a binary classification problem. This change of 299 perspective has been enabled by the introduction of an auxiliary threshold that is 300 optimally tailored to each association. Thus, discrimination can be measured with the 301 χ 2 statistic and its significance with the χ 2 test, which provides a better alignment of 302 the statistical and biological significance of a drug-gene association. Furthermore, we 303 have shown that, since φ is linked to χ 2 , the significance of a φ value can also be 304 calculated with the χ 2 test. 305
Next, the χ 2 test has been applied to the identification of genomic markers from 306 GDSC data and these markers compared to those arising from the MANOVA test [9] . 307
Unlike the χ 2 test, statistical tests from the ANOVA family are parametric and thus 308 expected to lead to inaccuracies when the data do not conform to the underlying 309 modelling assumptions [27, 28] . Unlike the MANOVA test, the χ 2 test has the 310 drawback of requiring the binarisation of logIC 50 values, which leads to all 311 misclassification errors having the same weight on the χ 2 statistic regardless of the 312 magnitude of this error. The largest discrepancies arising from both sets of p-values 313 have been discussed in detail as shown in and may also become true positives with the arrival of more data. 317
Using the new benchmark, we have carried out a systematic comparison across 8637 318 drug-gene associations for which a p-value from the MANOVA test had been 319 calculated in the GDSC study [9] . The MANOVA test highlighted 396 of these 320 associations as statistically significant, for 403 from the χ 2 test looking at the same 321 data. However, only 171 associations were deemed statistically significant by both 322 tests. Ultimately, we have found that 216 of the 396 MANOVA-significant markers 323 offer better than random performance. These drug-gene associations are those with 324 positive MCC in additional files 1 and 3. 325 We have also found that 229 of the 403 χ 2 -significant markers offer better than 326 random performance. Of these 229, 128 are new markers only detected by the χ 2 test 327 (see additional file 2) and hence are false negatives of the MANOVA test. 328
Temsirolimus-CDK2NA, 17AAG-CDK2NA or BMS-754807-EWS_FLI1 are among 329 the most predictive of these new in vitro markers. Furthermore, we also identified 7 330 new markers with MCC better than random classification for the 5 drugs for which 331 the MANOVA test did not find any marker [9]: NU-7441, Cyclopamine, BI-2536, 332 Gemcitabine and Epothilone B. Overall, the predictive value of the markers revealed 333 by the χ 2 test is higher than that arising from the MANOVA test and also that the 334 consensus of both tests is more predictive than any of these two tests alone (see Figure  335 6). The former means that the χ 2 test should be preferred over the MANOVA test for 336 this problem, the latter showing that the consensus of both tests highlights markers 337 that are more likely to be predictive than those that are significant by only one of the 338
tests. 339
Regarding best practices to compare two statistical tests for biomarker discovery, it 340 could be argued that it is better to base the comparison on the ability of the tests to 341 identify clinical markers. However, there are several reasons why this is inadequate. 342
First of all, only a fraction of GDSC drugs have FDA-approved markers. Second, 343
whereas clinical markers are so discriminative that are easily found by both methods, 344 the challenge is to identify more subtle markers in the data. Indeed, the goal of the 345 GDSC study was to search for still unknown markers to increase the ratio of patients 346 that could benefit from personalised treatments (low for most clinical markers) as well 347 as to find new markers for those drugs without clinical markers. Lastly, a gene 348 mutation discriminative of in vitro drug response may be discriminative of human 349 drug response, without still having been assessed in the clinic. Thus, a validation 350 based on comparing the tests on clinical markers will be blind to the MANOVA test 351 missing these discoveries. 352
Predictive biomarkers are increasingly important tools in drug development and 353 clinical research [39, 40] . During the development of methods for cancer diagnosis 354 and treatment, a vast amount of cancer genomics data is now being generated [41] and 355 thus there is an urgent need for their accurate analysis [42] . In the area of drug 356 sensitivity marker discovery, recent multilateral efforts have been made [43, 44] to 357 investigate the consistency of high-throughput pharmacogenomic data, which are 358 collectively important to promote an optimal use of this valuable data by the relevant 359 communities [45] . However, the impact of the strong modelling assumptions made by 360 standard parametric tests on the discovery of genomic markers from data has not been 361 analysed until now. Therefore, this study is important in a number of ways. First, 362 these new genomic markers of in vitro drug response represent testable hypothesis 363 that can now be evaluated on more relevant disease models to humans. Second, they 364 may also constitute further evidence supporting newly proposed oncology targets 365 [46] . Third, beyond the exploitation of these results, the widespread application of this 366 methodology should lead to the discovery of new predictive biomarkers of in vitro 367 drug response on existing data, as it has been the case here with the GDSC. Indeed, 368
this new approach has been demonstrated on a large-scale drug screening against 369 human cancer cell lines, but it can also be applied to other biomarker discovery 370 problems such as those adopting more accurate disease models (e.g. primary tumours 371 [47, 48] , patient-derived xenografts [49, 50] all possible drug-cell pairs). Downloaded "IC 50 " values are more precisely the natural 387 logarithm of IC 50 in µM units (i.e. negative values represent drug responses more 388 potent than 1µM). We converted each of these values into their logarithm base 10 in 389 µM units, which we denote as logIC 50 (e.g. logIC 50 =1 corresponds to IC 50 =10µM), as 390 in this way differences between two drug response values are directly given as orders 391 of magnitude in the molar scale. 392 gdsc_manova_input_w1.csv also contains genetic mutation data for 68 cancer genes, 393 which were selected as the most frequently mutated cancer genes [9] , characterising 394 each of the 638 cell lines. For each gene-cell pair, a "x::y" description was provided by 395 the GDSC, where "x" identifies a coding variant and "y" indicates copy number 396 information from SNP6.0 data. As in Garnett et al. [9] , a gene for which a mutation is 397 not detected is considered to be wild-type (wt). A gene mutation is annotated if: a) a 398 protein sequence variant is detected (x ≠{wt,na}) or b) a deletion/amplification is 399 detected. The latter corresponds to a copy number (cn) variation different from the wt 400 value of y=0<cn<8. Furthermore, three translocations were considered (BCR_ABL, 401 MLL_AFF1 and EWS_FLI1). For each of these gene fusions, cell lines are identified 402 as fusion not-detected or the identified fusion is given (i.e. wt or mutated with respect 403 to the gene fusion, respectively). The microsatellite instability (msi) status of each cell 404 line was also determined. Full details can be found in the original publication [9] . 405 Statistically significant drug-gene associations with the MANOVA test 406 gdsc_manova_output_w1.csv contains 8701 drug-gene associations with p-values. As 407 we are considering all those involving the 130 unique drugs (i.e. removing the 408 camptothecin duplicate), we are left with 8637 drug-gene associations with p-values 409 of which 396 were above a FDR=20% Benjamini-Hochberg adjusted threshold 410 (0.00840749) and thus deemed significant according to this test. As usual [9], each 411 statistically significant drug-gene association was considered to be a genomic marker 412 of in vitro drug response. 413
Measuring the discriminative power of a genomic marker with the χ 2 test 414 Let the data for the association between the i th drug and the j th gene be 415 {( )} and the sets of mutated and wt cell lines with respect to the j th gene, MT j and WT j , be 416
Then, the logIC 50 threshold is defined as the mean of the median responses from each 417 set (see subsection "Improved measurement of discriminative power by the χ 2 test"): 418
Now if the median response of the MT j set is lower (i.e. more sensitive to the drug) 419 than that of the WT j set in the considered drug-gene association, then cell lines with 420 logIC 50 values lower than the threshold (by this definition, cell lines sensitive to the 421 drug) are positives and those with logIC 50 vales higher or equal than the threshold (i.e. This χ 2 statistic follows a χ 2 distribution with one degree of freedom and thus each p-450 value was computed with the R package pchisq from its corresponding χ 2 value, as 451
The process is sketched in Figure 2 and leads to an alternative set of p-values from the 452 χ 2 test (P χ2 ). To establish which associations are significant according to the χ 2 test, we 453 also calculated for this case the FDR=20% Benjamini-Hochberg adjusted threshold 454 (0.00940155), that is 455
To facilitate reproducibility and the use of this methodology to analyse other 456 pharmacogenomics data sets, the R script to calculate φ, χ 2 and P χ2 from 457 gdsc_manova_input_w1.csv is available on request. 458
Benchmark to validate genomic markers on more recent GDSC data
459
This benchmark is based on using more recent GDSC data as test sets. With this 460 purpose, we downloaded new data from the latest release using the same experimental 461 techniques to generate pharmacogenomic data and panel of selected genes as in 462 release 1 (gdsc_manova_input_w5.csv) . This release 5 contains 139 drugs tested on 463 708 cell lines comprising 79,401 logIC 50 values (80.7% of all possible drug-cell 464 pairs). For the 127 drugs in common between releases 1 and 5, two non-overlapping 465 data sets are generated per drug. Training sets using data in release 1 (the minimum, 466 average and maximum numbers of cell lines across training data sets are 237, 330 and 467 467, respectively), along with their logIC 50 s for the considered drug. These sets were 468 used to identify genomic markers as previously explained. Test sets contain the new 469 cell lines tested with the drug in release 5 (the minimum, average and maximum 470 numbers of cell lines in the test data sets are 42, 171 and 306, respectively). Thus, a 471 total of 254 data sets were assembled and analysed for this study. 472
Thereafter, the significant drug-gene associations from each statistical test are 473 evaluated on these test sets. Previously, a cell line sensitivity threshold was defined to 474 discriminate between those resistant or sensitive to a given drug. For each drug, we 475 calculated the threshold as the median of all the logIC 50 values from training set cell 476 lines. Consequently, cell lines with logIC 50 lower than such threshold are sensitive to 477 the drug of interest, whereas those with logIC 50 higher the threshold are resistant. 478
Lastly, classification performance of a marker on its test set is summarised with the 479 MCC (this is different from φ, which has the same expression but uses a different 480 threshold aimed instead at measuring the degree of separation between mutant and 481 WT cell lines in the training set). 482
Author contributions 491 P.J.B. conceived the study, designed its implementation and wrote the manuscript. 492 C.C.D. implemented the software and carried out the numerical experiments with the 493 assistance of A.P. All authors discussed results and commented on the manuscript. 494 are functions of these metrics and summarise binary classification performance, as 712 further described in the Methods section. BCR_ABL is a very strong marker of 713 Dasatinib sensitivity as shown in the scatter plot and highlighted by both statistical 714 tests (P MANOVA =1.4•10 -10 , P χ2 =6.4•10 -28 ), offering unusually high discrimination 715 between cell lines according to their relative drug sensitivity (φ=0.65). 716 to the markers evaluated with more data shown as black crosses). 726 test. Hence, mutated-FLT3 is a marker of sensitivity to the experimental drug 731 GW441756 according to the MANOVA test, but not according to the χ 2 test.In the 732 plotted training set, this marker offers practically no discriminative power as further 733 evidenced by a φ of just 0.05 and similar drug response (logIC 50 ) distributions of 734 mutated and WT cell lines. However, this marker provides an MCC of 0.10 on the test 735 and hence this is a false negative of the χ 2 test. (right) Conversely, to assess the 736 consistency of the MANOVA test, we searched for the drug-gene association with 737 largest -logP χ2 among those with a similar -logP MANOVA to that of GW441756-FLT3, 738 which is Dasatinib-BCR_ABL. Whereas the p-value for Dasatinib-BCR_ABL is of 739 the same magnitude as that for GW441756-FLT3 using the MANOVA test 740 (P MANOVA~1 0 -10 ), the p-values for the same associations using the χ 2 test differ is 741 almost 27 orders of magnitude. Thus, unlike the χ 2 test, the MANOVA test is unable 742 to detect the extreme difference in discriminative power offered by these two drug-743 gene associations. Indeed, the BCR_ABL translocation is a highly discriminative 744 marker of Dasatinib sensitivity (φ=0.65), as also evidenced by the barely overlapping 745 drug response distributions from each set of cell lines. This is confirmed in the test 746 set, where the Dasatinib-BCR_ABL marker obtains an MCC of 0.21. with the largest -logP χ2 among those not significant according to the MANOVA test. 752
Hence, mutated-CDKN2a.p14 is a potential marker of sensitivity to the marketed drug 753 Dasatinib according to the χ 2 test, but not according to the MANOVA test. However, 754 this marker has predictive value as it provides MCC=0.13 on the test set. Therefore, 755 the χ 2 test detected this potential false negative of the MANOVA test. (right) 756
Conversely, to assess the consistency of the MANOVA test, we searched for the drug-757 gene association with largest -logP MANOVA among those with a similar -logP χ2 to that 758 of Dasatinib-CDKN2a.p14, which is SB590885-BRAF. Whereas the p-values for 759 Dasatinib-CDKN2a.p14 and SB590885-BRAF differ in 27 orders of magnitude using 760 the MANOVA test, the p-values for the same associations have similar p-values using 761 the χ 2 test (P χ2~1 0 -9 ). Thus, unlike the χ 2 test, the MANOVA test is unable to detect 762 that both markers have similar discriminative power (SB590885-BRAF has a φ of 
768
The methods are evaluated by their ability to correctly classify more recently-tested 769 cell lines as sensitive or resistant to the considered drug via the MCC on the test set. 770
There is no overlap between test sets and those employed to identify all drug-gene 771 associations (training sets). The three compared methods are those based on the χ 2 test 772 be the most discriminative marker for the approved drug Gemcitabine (MCC=0.18 on 797 the test set), which was missed by the MANOVA test (P MANOVA =0.06). (right) The 798 mutational status of the NOTCH1 gene is found to be the most discriminative marker 799 for the development drug BI-2536 (MCC=0.23 on the test set), which was also missed 800 by the MANOVA test (P MANOVA =0.03). 801
